Genflow Biosciences reported progress in its proof-of-concept dog trial evaluating its SIRT6-centenarian gene therapy (GF-1004), according to the company. The randomized, controlled study, involving 28 beagles aged ten years or older, administered three different modalities of the therapy in March with no adverse effects observed. Controls remained untreated. The dogs will now undergo a five-month follow-up period expected to conclude in January 2026.
The strategic objective of the trial is to generate compelling preclinical data that could support a licensing agreement with a major animal health company. GF-1004 is described as a first-in-class gene therapy candidate targeting fundamental aging mechanisms shared by dogs and humans, with the potential to extend lifespan and enhance quality of life in companion animals.
Key study goals include confirming the feasibility of GF-1004 administration, validating safety and efficacy at the administered dose, and demonstrating multi-dimensional benefits. These include reduced biological age (using the GRIM methylation clock), increased muscle strength and mass, enhanced mitochondrial function, improved coat quality, and better overall health metrics.
The company said that success in this trial would provide a strong foundation for possible expansion into human health applications, unlocking additional markets in longevity therapeutics.
